Amylyx Pharmaceuticals, Inc. Stock-Based Compensation
Amylyx Pharmaceuticals, Inc. (AMLX) reported Stock-Based Compensation of $14.44 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-08-06
- Amylyx Pharmaceuticals, Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $8.32M, a 13.17% increase year-over-year.
- Amylyx Pharmaceuticals, Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $6.12M, a 10.43% decline year-over-year.
- Amylyx Pharmaceuticals, Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $6.39M, a 5.27% decline year-over-year.
- Amylyx Pharmaceuticals, Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $7.08M, a 4.01% increase year-over-year.
- Amylyx Pharmaceuticals, Inc. share-based payment arrangement, noncash expense for fiscal 2025 was $27.64M, a 16.32% decline from fiscal 2024.
- Amylyx Pharmaceuticals, Inc. share-based payment arrangement, noncash expense for fiscal 2024 was $33.04M, a 11.09% decline from fiscal 2023.
- Amylyx Pharmaceuticals, Inc. share-based payment arrangement, noncash expense for fiscal 2023 was $37.16M, a 71.14% increase from fiscal 2022.
- Amylyx Pharmaceuticals, Inc. share-based payment arrangement, noncash expense for fiscal 2022 was $21.71M, a 592.41% increase from fiscal 2021.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $8.32M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $14.44M 10-Q · filed 2026-08-06 | $20.82M derived: sum of 3 quarters · filed 2026-08-06 | $27.90M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $6.12M 10-Q · filed 2026-05-07 | $12.51M derived: sum of 2 quarters · filed 2026-05-07 | $19.58M derived: sum of 3 quarters · filed 2026-05-07 | $26.93M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $6.39M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $13.46M derived: sum of 2 quarters · filed 2026-03-03 | $20.81M derived: sum of 3 quarters · filed 2026-08-06 | $27.64M 10-K · filed 2026-03-03 |
| 2025-09-30 | $7.08M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $14.43M derived: sum of 2 quarters · filed 2026-08-06 | $21.26M 10-Q · filed 2025-11-06 | $28.00M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $7.35M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $14.18M 10-Q · filed 2026-08-06 | $20.92M derived: sum of 3 quarters · filed 2026-08-06 | $27.73M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $6.83M 10-Q · filed 2026-05-07 | $13.57M derived: sum of 2 quarters · filed 2026-05-07 | $20.38M derived: sum of 3 quarters · filed 2026-05-07 | $29.95M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $6.74M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $13.54M derived: sum of 2 quarters · filed 2026-03-03 | $23.11M derived: sum of 3 quarters · filed 2026-03-03 | $33.04M 10-K · filed 2026-03-03 |
| 2024-09-30 | $6.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $16.37M derived: sum of 2 quarters · filed 2025-11-06 | $26.30M 10-Q · filed 2025-11-06 | $35.83M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $9.57M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $19.49M 10-Q · filed 2025-08-07 | $29.03M derived: sum of 3 quarters · filed 2025-08-07 | $39.20M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $9.92M 10-Q · filed 2025-05-08 | $19.46M derived: sum of 2 quarters · filed 2025-05-08 | $29.63M derived: sum of 3 quarters · filed 2025-05-08 | $39.58M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $9.53M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-04 | $19.71M derived: sum of 2 quarters · filed 2025-03-04 | $29.66M derived: sum of 3 quarters · filed 2025-03-04 | $37.16M 10-K · filed 2025-03-04 |
| 2023-09-30 | $10.18M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $20.13M derived: sum of 2 quarters · filed 2024-11-07 | $27.63M 10-Q · filed 2024-11-07 | $33.72M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $9.95M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $17.45M 10-Q · filed 2024-08-08 | $23.54M derived: sum of 3 quarters · filed 2024-08-08 | $29.07M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $7.50M 10-Q · filed 2024-05-09 | $13.59M derived: sum of 2 quarters · filed 2024-05-09 | $19.12M derived: sum of 3 quarters · filed 2024-05-09 | $24.82M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $6.09M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $11.62M derived: sum of 2 quarters · filed 2024-02-22 | $17.32M derived: sum of 3 quarters · filed 2024-02-22 | $21.71M 10-K · filed 2024-02-22 |
| 2022-09-30 | $5.52M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $11.23M derived: sum of 2 quarters · filed 2023-11-09 | $15.62M 10-Q · filed 2023-11-09 | $16.71M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-06-30 | $5.71M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $10.10M 10-Q · filed 2023-08-10 | $11.19M derived: sum of 3 quarters · filed 2024-02-22 | $11.99M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-03-31 | $4.39M 10-Q · filed 2023-05-11 | $5.48M derived: sum of 2 quarters · filed 2024-02-22 | $6.29M derived: sum of 3 quarters · filed 2024-02-22 | $6.94M derived: sum of 4 quarters · filed 2024-02-22 |
| 2021-12-31 | $1.09M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $1.89M derived: sum of 2 quarters · filed 2024-02-22 | $2.55M derived: sum of 3 quarters · filed 2024-02-22 | $3.14M 10-K · filed 2024-02-22 |
| 2021-09-30 | $802.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $1.46M derived: sum of 2 quarters · filed 2022-11-10 | $2.04M 10-Q · filed 2022-11-10 | |
| 2021-06-30 | $657.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $1.24M 10-Q · filed 2022-08-11 | ||
| 2021-03-31 | $586.00K 10-Q · filed 2022-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |